Sitemap

IsoPet® is our division dedicated to treating cancers in animals using our patented Precision Radionuclide Therapy™ (PRnT). Our innovative approach in the treatment of cancerous tumors focuses on delivering targeted radiation directly to cancerous tumors in a single treatment while minimizing damage to surrounding healthy tissues.

Deliver your active pharmaceutical with quick-dissolving, biodegradable thermogel consisting of poly(lactide-co-glycolide)-graft-poly(ethylene glycol). Initially developed at Pacific Northwest Laboratories and further refined by a collaboration between Vivos, Inc. and Akina, Inc.

RadioGel® is our division dedicated to treating cancer in humans using our patented Precision Radionuclide Therapy™ (PRnT). RadioGel® is currently not approved for human use or commercial distribution in the United States. It is being studied under an FDA-approved Investigational Device Exemption (IDE) for clinical trials only.